Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 355 participants.
Also called NCT01730040
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 355 participants
- Sponsor
- Registry
-
NCT01730040
-
- Other papers using this trial's data
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, France, Germany, Italy, Mexico, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01730040. Randomized; quadruple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-08-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct01730040- Content hash
a6098a9789592deb0a3ab2a4d4e305de7cbf454123aefceeb5489f8519bcb525